Abstract
The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma resulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment are more likely to benefit from treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
